CytomX Therapeutics Inc. announced that initial translational data from the ongoing Phase 1 study of CX-801, a masked interferon alpha-2b PROBODY® cytokine, in patients with advanced melanoma will be presented at the Society for Immunotherapy of Cancer $(SITC)$ 40th Anniversary Annual Meeting, scheduled for November 7-9, 2025. According to the company, early results indicate that CX-801 is generally well tolerated and demonstrates activation of tumor-selective interferon signaling in patients with advanced melanoma, including those refractory to prior immune checkpoint inhibitor therapy. These findings support the rationale for an ongoing Phase 1 combination study of CX-801 with KEYTRUDA® (pembrolizumab). The company plans to present Phase 1 clinical data of the CX-801 and KEYTRUDA® combination in 2026.